Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. - Wikidata - wikimedia - TriplyDB

Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity.

Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity.

http://www.wikidata.org/entity/Q44736849

about

Brivaracetam: a rational drug discovery success story New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels Diverse mechanisms of antiepileptic drugs in the development pipeline Molecular targets for antiepileptic drug development Profile of brivaracetam and its potential in the treatment of epilepsy Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.Brivaracetam (UCB 34714)SV2 regulates neurotransmitter release via multiple mechanisms.Emerging drugs for epilepsy.Expression of SV2 isoforms during rodent brain development.New antiepileptic drugs that are second generation to existing antiepileptic drugs.Novel anticonvulsant drugs targeting voltage-dependent ion channels.Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.Total syntheses of (-)-pyrimidoblamic acid and P-3A.New and investigational antiepileptic drugs.Pharmacotherapy of epilepsy: newly approved and developmental agents.Brivaracetam for the treatment of epilepsy.Rhodium-catalysed asymmetric hydrogenation as a valuable synthetic tool for the preparation of chiral drugs.The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy.Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures.Brivaracetam for the treatment of epilepsy.Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus.Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going?Synaptic Vesicle-Recycling Machinery Components as Potential Therapeutic Targets.The importance of screening solid-state phases of a racemic modification of a chiral drug: thermodynamic and structural characterization of solid-state phases of etiracetam.Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures.Stereochemistry of the Brivaracetam Diastereoisomers.The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males.Design, synthesis and anticonvulsant activity of some new 6,8-halo-substituted-2h-[1,2,4]triazino[5,6-b]indole-3(5h)-one/-thione and 6,8-halo-substituted 5-methyl-2h-[1,2,4]triazino[5,6-b]indol-3(5h)-one/-thione.Brivaracetam disposition in mild to severe hepatic impairment.A new antibacterial amino phenyl pyrrolidone derivative from a novel marine gliding bacterium Rapidithrix thailandica.Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial.Effect of brivaracetam on CYP3A activity, measured by oral midazolam.Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy.Design and synthesis of (5-amino-1, 2, 4-triazin-6-yl)(2-(benzo[d] isoxazol-3-yl) pyrrolidin-1-yl)methanone derivatives as sodium channel blocker and anticonvulsant agents.A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures.Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.Anti-ictogenic and antiepileptogenic properties of brivaracetam in mature and immature rats.

P2860

Q24642768-49EAA03C-107D-430E-8CC0-45BCB2EC2CD2 Q24654230-19BEA2D1-96AE-434B-86B9-2A8DEE0D7FD6 Q24675330-0BA094D1-8083-482B-BB81-09BA84E417EA Q24683346-1748FB4D-1B5C-48E0-BE9F-54D9F0905333 Q26776317-9864D722-0AB0-4729-97E6-EFE3811B24A0 Q28068507-CC220F74-9421-44BC-936B-33EB53DC9C32 Q28281249-5E146FB3-7D88-438E-BB1C-8EF04E7F6D30 Q28281403-E6C04BB5-761F-43CF-BF8B-1D504D5D29F9 Q34304904-2645806D-7FAA-4876-ABB4-2150B8279196 Q34688725-0AF288AF-5170-46E1-A767-0FFBA5D02732 Q34927836-EDA84D04-38D8-41A9-B2B8-244EE955DFFB Q36491829-9C93B235-CD5A-4368-AEF1-32C507108855 Q36600282-5E8344B3-843A-4967-993B-7454CE994C51 Q37113376-CB02D038-9F60-4167-A356-84F4C8F7D643 Q37613626-4DFB92E9-DE49-4BEB-A513-507C20979979 Q37638688-1FC2013F-91F2-4E1C-A8AE-4BAC966183F9 Q37831297-A527B410-B711-4DEA-B1E3-05DBB15D01CC Q37891095-985D8B14-4A70-4AFB-BDD8-9D93601BD443 Q38058272-4D1509DC-657D-4387-A8B1-70CFFE9C66C2 Q38614499-66C98722-2257-46CC-9386-C3641034BE0C Q38626838-6FBBE202-4B0C-45D5-AE9E-8E59757D2CA1 Q38694479-8B2AE341-A5FF-4066-8DC9-558F6F1964B6 Q38739649-83862715-A25E-4C2A-BBA3-71D63E3E5B33 Q38752407-96FB9A20-48D4-4231-8904-95CF4DAA834E Q38974450-4968421F-A385-4C51-8E03-E3B4C8171336 Q39164408-E8734542-6BF2-40E7-BD72-0BA35A54E35F Q39380722-D06953B7-79D9-4EE8-BEBA-246A33B64BA6 Q39707630-C28F0CF0-812B-490B-A95D-6FD59898A4A3 Q40134330-3ADF3DE3-19D9-4EB1-A890-22B0209CD1C9 Q41117944-3D68A1EE-D93C-4552-BE54-519C7F843ECE Q41895052-6BD297D5-9110-4CFE-949E-2F7E7B6AF4FD Q44231616-CE3161F0-2C30-4E74-BA2D-7907F2AE810D Q44274003-90C2F28F-C02B-44E4-A3DC-3BCEC19C6376 Q44773924-AA9D9728-98FE-40F0-8B4E-42001E442183 Q47774665-BDB9B7D4-C421-4920-9FB9-D33C54F49C63 Q47853821-B5189A02-8ADF-4B31-B55B-EB29A52D3CE1 Q47860209-A4D7DD22-5DA9-4D73-9851-FE525226EDB3 Q47926989-F80BB0B2-9C67-40E9-BB74-685D8B309C03 Q48130509-71A0E5B2-EB11-47C9-9A10-01A57F92357C Q48258054-31261570-F414-429C-94C1-296C33C7A2D1

P2860

Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity.

http://www.wikidata.org/entity/Q44736849

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

Discovery of 4-substituted pyr ...... ficant antiepileptic activity.

@en

Discovery of 4-substituted pyr ...... ficant antiepileptic activity.

@nl

type

label

Discovery of 4-substituted pyr ...... ficant antiepileptic activity.

@en

Discovery of 4-substituted pyr ...... ficant antiepileptic activity.

@nl

prefLabel

Discovery of 4-substituted pyr ...... ficant antiepileptic activity.

@en

Discovery of 4-substituted pyr ...... ficant antiepileptic activity.

@nl

P1433

Q44736849-D92B79AB-F22B-45D2-8BF2-E0D28E5B6948

P1476

Q44736849-25A5A96D-BE18-408A-8DBC-494558894286

P2093

Q44736849-052A4992-E97E-4D87-8F63-79CAD15DF60F

Q44736849-0C172AB7-A397-48D9-9864-BA1536EBA080

Q44736849-159A63EC-AF91-4825-8FF9-491AB94CDBEC

Q44736849-4CF09C93-807D-4870-B1FD-5C794C691D40

Q44736849-52EC7213-9D75-41F6-9D57-FFFBBCC5FE7F

Q44736849-A02B449B-DD8E-4A55-A48F-EF7666C7EBAE

Q44736849-AF3EB15D-9B45-4EEE-AF98-2B0A0A184658

Q44736849-C25D0190-6C89-4D1A-A2D3-FEFF83967697

Q44736849-CE46CBA0-2675-4A19-87CB-1CE55813A094

Q44736849-E20689F1-5492-492C-84E4-8408CAF6092C

P304

Q44736849-B34204F3-89D6-4DED-99DF-15D1326BE60C

P31

Q44736849-AA6D2CDB-E845-4307-92E4-E3BBC4F62EEA

P356

Q44736849-5C3D3E53-0A6A-4185-9935-09E8DD0D9921

P407

Q44736849-CA501122-FB36-439F-AD8F-4FD698596728

P433

Q44736849-11F91657-3141-4742-AEDF-E6823A3849C0

P478

Q44736849-36351AD9-233B-4F02-85F4-F2FC0F8011E0

P577

Q44736849-9954665F-1B5E-491E-BCA9-990D812F1CC8

P698

Q44736849-B8324F6F-BD4E-4710-9846-36E9D00CE794

P356

P1433

Journal of Medicinal Chemistry

P1476

Discovery of 4-substituted pyr ...... ficant antiepileptic activity.

@en

P2093

Alain C Matagne

http://www.w3.org/2001/XMLSchema#string

Anne M Frycia

http://www.w3.org/2001/XMLSchema#string

Benoit M Kenda

http://www.w3.org/2001/XMLSchema#string

Bruno Fuks

http://www.w3.org/2001/XMLSchema#string

Bénédicte I Lallemand

http://www.w3.org/2001/XMLSchema#string

Edmond Differding

http://www.w3.org/2001/XMLSchema#string

Florence G Moureau

http://www.w3.org/2001/XMLSchema#string

Henrik V Klitgaard

http://www.w3.org/2001/XMLSchema#string

Michel R Gillard

http://www.w3.org/2001/XMLSchema#string

Patrice E Talaga

http://www.w3.org/2001/XMLSchema#string

P304

530-549

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM030913E

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2004-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14736235

http://www.w3.org/2001/XMLSchema#string